Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
In this study, patients with hepatocellular carcinoma were used as the research object to
explore the effectiveness and safety of idarubicin hepatic artery perfusion combined with
lipiodol embolization, and to preliminarily explore the possibility of idarubicin in the
treatment of hepatocellular carcinoma. Provide evidence-based medicine for the discovery of
better TACE combined chemotherapy regimens for the treatment of hepatocellular carcinoma.